Back to Stacks
Fat LossAnecdotal

Semaglutide + Tesamorelin: Targeted Fat Loss

A dual-mechanism fat loss stack combining semaglutide's appetite suppression and GLP-1-mediated metabolic benefits with tesamorelin's targeted visceral fat reduction through GHRH agonism. Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity, while tesamorelin specifically mobilises deep abdominal visceral adipose tissue by stimulating pulsatile GH release. The two agents operate through entirely non-overlapping pathways and address different fat compartments.

Safety Notes

Semaglutide is an FDA-approved prescription GLP-1 agonist carrying a boxed warning for thyroid C-cell tumour risk (observed in rodents; human risk not established). It requires a licensed prescriber and is contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy; its use for general fat loss is off-label and outside its approved indication. This is a prescription-only combination not appropriate for unsupervised use.

Peptides in This Stack

  1. 1
    SemaglutideFat Loss

    Reduces appetite and caloric intake via GLP-1 receptor agonism, improves insulin sensitivity, and drives broad body composition improvements — serving as the primary overall fat loss driver of the stack.

  2. 2
    TesamorelinFat Loss

    Specifically targets visceral adipose tissue via GHRH-stimulated GH pulses that preferentially mobilise deep abdominal fat, addressing a metabolically harmful fat depot that GLP-1 agonism alone may not fully resolve.

Research References

Established

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial)NEJM 2021 · PMID 33567185
  • Effects of tesamorelin (TH9507) in HIV-infected patients with abdominal fat accumulationJ Acquir Immune Defic Syndr 2010 · PMID 20616699
  • Effects of tesamorelin on non-alcoholic fatty liver disease in HIV-infected patientsLancet HIV 2019 · PMID 31285190

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.